This global network will be tested as vaccines begin making the journey from warehouse to airports and cargo terminals
Less than nine months ago, the World Health Organization officially declared the outbreak of the novel coronavirus that causes COVID-19 a global pandemic. Several biopharmaceutical companies had already begun to develop experimental vaccines for COVID-19.
Here’s what this milestone means — and doesn’t mean.
IMAGE SOURCE: GETTY IMAGES.
The Wall Street Journal reported on Friday that United Airlines had initiated charter flights to transport BNT162b2, the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Over the weekend, other news organizations reported confirmation by the Federal Aviation Administration of the “first mass air shipment” of a COVID vaccine.
Doses of BNT162b2 are being flown from Belgium, where Pfizer operates a manufacturing facility, to Chicago. But that’s just the first stop. From there, the COVID vaccine will be delivered to distribution hubs across the U.S.
BNT162b2 requires ultra-cold storage. Pfizer and BioNTech developed temperature-controlled thermal shippers that use dry ice to maintain temperatures of around minus 94 degrees Fahrenheit for up to 10 days. The FAA reportedly gave permission for United Airlines’ cargo planes to carry 15,000 pounds of dry ice per flight — five times more than is normally allowed.
What it means and doesn’t mean
This major transportation initiative is definitely a key milestone in the race to bring a coronavirus vaccine to the public. However, it doesn’t mean that Pfizer and BioNTech have received any kind of U.S. authorization to make BNT162b2 available to Americans yet.
The two drugmakers filed for emergency use authorization (EUA) with the Food and Drug Administration for BNT162b2 on Nov. 20. The FDA has scheduled an advisory committee meeting for Dec. 10 to review the EUA filing. The agency will make its decision shortly after that meeting.
Why did Pfizer begin shipping BNT162b2 weeks before a potential EUA? The COVID vaccine can’t be delivered to healthcare providers yet. However, it can be pre-positioned at hubs to allow that last distribution phase to start sooner, when and if BNT162b2 is given authorization.
Pfizer stated on Nov. 20 that it planned to primarily ship from its Kalamazoo, Michigan, manufacturing site directly to the healthcare sites where its vaccine would be administered. The big drugmaker also said that it intended to use its distribution center in Pleasant Prairie, Wisconsin. This approach would enable Pfizer to deliver BNT162b2 to any vaccine administration site in the U.S. “within a day or two,” according to the company.
Shipping BNT162b2 to more distribution hubs spread across the U.S. should speed up delivery to the points of use even more (again, assuming the vaccine wins an EUA). That’s great news for millions of Americans who are anxiously awaiting a safe and effective vaccine.
One big investing takeaway
There’s one takeaway for investors when it comes to these early shipments of BNT162b2: Pfizer is the clear leader in the coronavirus vaccine race at this point. It’s important to remember that Pfizer and BioNTech stand to receive at least $1.95 billion from the U.S. government to supply 100 million doses of BNT162b2. That money could begin to flow very soon.
The amount could also increase. The U.S. has an option to purchase up to 500 million additional doses of BNT162b2. Pfizer and BioNTech also have major supply agreements with other countries.
This doesn’t necessarily mean that the big pharma stock will be the biggest COVID vaccine winner. It takes a lot more to move the needle for a giant like Pfizer than it does for the small biotechs that are developing coronavirus vaccines. However, it’s nice to be in first place. And that’s where Pfizer indisputably is right now.
Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Motley Fool Returns
STOCK ADVISORS&P 500
Stock Advisor launched in February of 2002. Returns as of 12/01/2020.
Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock AdvisorCalculated by Time-Weighted Return
United Airlines Holdings, Inc.
3 Pharma Stocks With Dividends Above 4% to Buy Now
Pfizer’s Vaccine Candidate Is Effective — But It Has Issues
Where Will Pfizer Be in 5 Years?
3 Dividend Stocks Ideal for Retirees
Coronavirus Vaccine Stocks: Is There Room For Multiple Winners?
Once the FDA Green Lights a Vaccine, This Is the Next Big Hurdle for Investors
Demonstrating effectiveness is no small task, but the next challenge may be even greater.
Nov 24, 2020 at 6:25AM
The role of logistics in global crises often goes unnoticed. In the attempt to increase vaccination rates throughout the world, supply chains often have more influence on which vaccines make a difference than the drug itself. Because of this, vaccine development is usually done with supply chain constraints in mind — but the coronavirus pandemic has thrown some of these rules aside.
So far, the vaccines that have demonstrated efficacy require some kind of carefully constructed cold chain. Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) vaccine requires cold storage at negative 70 degrees Celsius. Moderna’s (NASDAQ:MRNA) vaccine remains stable for 30 days at the more reasonable temperatures between 2 degrees and 8 degrees Celsius, or six months at colder temperatures. AstraZeneca’s (NASDAQ:AZN) candidate, on the other hand, can be stored at regular refrigerator temperatures.
Earlier in the pandemic, logistics companies needed to move personal protective equipment (PPE) all over the globe when demand quickly exceeded supply. Masks, gloves, and gowns don’t require any special temperature treatment, but the distribution was still not smooth. In the U.S., few supplies in the national stockpile and a lack of federal coordination led to a frenzy of states bidding against other states, hospitals fending for themselves, and in some cases, individual companies inking deals with foreign governments to obtain their own supply of PPE. As vaccine candidates creep tantalizingly closer to U.S. Food and Drug Administration (FDA) approval, logistics companies are determined to be prepared for the challenge this time around.
IMAGE SOURCE: GETTY IMAGES.
Vaccines pose unique challenges
Logistics companies have gotten used to shipping biological material over the years. (Biologics, drugs that contain or are made from living organisms, are estimated to be a $255 billion market growing at more than 7% per year.)
It has been good business for companies like United Parcel Service (NYSE:UPS), FedEx (NYSE:FDX), and DHL Global Forwarding to invest in infrastructure supporting the transportation of this material all over the world. These companies often use freezer farms for tissue and blood samples, as well as vaccines. To support the pharmaceutical industry, FedEx built its Cold Chain Center in Tennessee, near its shipping hub. Most of the temperature controlled rooms are designed for one of two ranges: 15 degrees to 25 degrees Celsius or 2 degrees to 8 degrees Celsius. In addition to cold storage, UPS boasts its own temperature-controlled shipping container, the PharmaPort, that broadcasts its status and location no matter where it is in the world.
and eventually to clinics and hospitals. Vaccines for measles, tuberculosis, and yellow fever are shipped freeze-dried, with liquids added to the powdered vaccines before injection. Unlike those vaccines, shippers weren’t sure which vaccines would be approved. This has made it difficult to prepare for unknowns like the quantity of vials, packaging dimensions, temperature constraints, and how quickly vaccines would need to be administered. Despite the uncertainty, logistics companies have invested in being prepared.
Logistics companies say they are ready
Logistics providers are building new freezer farms and lining up capacity in preparation for delivering vaccine doses around the world. UPS is bolstering freezer facilities in Louisville and Venlo in the Netherlands, close to company air hubs. The 600 total freezers in Louisville and the Netherlands can store up to 48,000 vials each.
The company is also buying a limited amount of freezers for the U.K., Germany, and South America to ensure overnight delivery nearly anywhere in the world. UPS sees the investment in this cold chain as a competitive advantage given the growth of biologics in the pharmaceutical industry. For its part, FedEx is adding freezers, refrigerator trucks, sensors, and thermal blankets to its arsenal. The company has also built frozen rooms capable of temperatures between negative 25 and negative 10 degrees Celsius. In anticipation of the challenges, Pfizer has created a special case for their vaccine dubbed “the pizza box.”
Experts think herd immunity may not be achieved until 70 percent of humanity is vaccinated. To understand how many doses that is, the number of vaccine packages required, lined up end-to-end, would stretch around the world 10 times. Regardless, the World Health Organization (WHO) aims to deliver two billion doses in 2021. Pfizer has said it can create about 50 million doses by the end of the year with half going to other countries. Since the vaccine is administered in a two-dose schedule, that would mean about 12.5 million Americans could be vaccinated by early January. Moderna’s vaccine could add another 10 billion to that number.
McKesson (NYSE:MCK) has expanded its existing relationship with the U.S. Centers for Disease Control (CDC) to handle the last mile of distribution of vaccines to the hospitals and clinics where they will be administered. As the primary distributor of the seasonal flu vaccine, the company has experience on its side.
Determining how well it’s going
It’s much easier to make thousands of doses for a clinical trial than the millions of doses per day that a global vaccination program will require. Once they are produced, maintaining the integrity of gene-based vaccines in super-cold freezers and getting them to those most at risk will be one of the greatest logistic challenges in human history. There is one sign in particular we can look for to know how it’s going.
We know from drug makers that enough vaccines to inoculate around 22 million Americans should be produced by the end of the year. Ideally, both the number of doses and the number of vaccinations will be made public. This would allow us to track the initial push to vaccinate healthcare workers. There are currently more than one million doctors, and nearly four million nurses in the U.S. Add in hospital custodians, paramedics, nurse assistants, and others, and you get closer to the approximately 16 million Americans who work in healthcare — more than six million in hospitals.